Lilly co-funds China's Innovent in biologics expansion
This article was originally published in Scrip
The regional venture aim of Eli Lilly has come in to participate in a second round of venture capital raised by the Chinese bioventure Innovent Biologics. Innovent is positioning itself as a developer and international supplier of monoclonal antibodies and biosimilars, in a strategy that won the company $30 million in startup capital late last year from investors including Fidelity Growth Partners Asia and the China-Singapore Suzhou Industrial Park (Suzhou BioBay), where Innovent is located.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.